ArticleFrontiers in cardiovascular medicine2025
Elevated serum asprosin and ANGPTL8 gene expression as novel biomarkers for the diagnosis and prognosis of acute coronary syndrome.
Article in Frontiers in cardiovascular medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Asprosin as a Potential Link Between Vascular Inflammation and Disease Activity in Behçet's Disease.Journal of clinical laboratory analysis · 2026Article
- Elevated asprosin in hypertension: evidence from an exploratory case-control study.Scientific reports · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Managing acute coronary syndrome (ACS) remains a major global healthcare concern. Identifying novel biomarkers is crucial to improving early detection and patient classification. Traditional markers such as cardiac troponins have limitations, including delayed detectability in blood samples, necessitating the search for better alternatives. Asprosin and angiopoietin-like protein 8 (ANGPTL8) have recently emerged as potential biomarkers for ACS diagnosis. Methods: This comparative study included 100 participants, equally divided into ACS patients and healthy controls with matched demographics. Enzyme-linked immunosorbent assay (ELISA) was employed to quantify asprosin concentrations, while real-time polymerase chain reaction (RT-PCR) assessed ANGPTL8 gene expression levels. Receiver operating characteristic (ROC) curve analysis evaluated the diagnostic utility of these biomarkers, and Spearman's correlation was used to examine relationships between variables. Results: Asprosin levels were significantly elevated in ACS patients (5.27 ± 0.67 ng/ml) compared to healthy individuals (3.82 ± 1.20 ng/ml, Discussion: The findings highlight the potential of asprosin and ANGPTL8 as promising diagnostic and prognostic markers for ACS. Their high sensitivity and correlation suggest a complementary role in early ACS detection. However, further clinical trials are required to validate these biomarkers in broader patient populations and determine their practical implementation in medical settings. Conclusion: Asprosin and ANGPTL8 exhibit strong diagnostic potential in ACS detection, potentially improving early intervention strategies. Future studies should focus on their integration into clinical practice for enhanced patient outcomes.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.